Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes

Julia Diegmann1, Kerstin Junker, Ivan F Loncarevic

  • 1Core Unit Chip Application, Institute of Human Genetics and Anthropology, Friedrich Schiller University, Jena 07740, Germany.

Neoplasia (New York, N.Y.)
|November 30, 2006
PubMed

Insights

Renal cell carcinoma (RCC) tumors can evade immune destruction by inducing lymphocyte apoptosis. Overexpressed CD70 in RCC promotes this apoptosis via CD27 interaction, hindering anti-tumor responses.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Tumors escape immune surveillance by inducing lymphocyte apoptosis.
  • Renal cell carcinoma (RCC) exhibits immune escape mechanisms, with few identified genes like FasL involved.
  • Previous studies indicated overexpression of apoptosis-inducing genes in RCC.

Purpose of the Study:

  • To investigate the role of CD70 in RCC-mediated immune escape.
  • To determine if CD70 overexpression contributes to lymphocyte apoptosis in RCC.
  • To elucidate the molecular interactions involved in CD70-induced apoptosis.

Main Methods:

  • Coculturing lymphocytes with RCC cell lines (A498 and CAKI2).
  • Adding recombinant soluble CD70 to lymphocytes and T-cell lines.
  • Utilizing anti-CD27 and anti-CD70 antibodies to block apoptosis.

Main Results:

  • Lymphocyte apoptosis increased upon coculture with RCC cell lines.
  • Recombinant soluble CD70 significantly enhanced lymphocyte apoptosis.
  • Anti-CD27 and anti-CD70 antibodies partially inhibited the induced apoptosis.
  • CD70 overexpression in RCC promotes lymphocyte apoptosis.

Conclusions:

  • CD70 and its receptor CD27 play a crucial role in lymphocyte apoptosis within the tumor microenvironment.
  • Tumor-secreted CD70 contributes to immune evasion in RCC by inducing apoptosis.
  • This mechanism may impair effective lymphocyte-mediated anti-tumor responses in RCC patients.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...